Drug Profile
Research programme: anticancer therapeutics - NanoCarrier/Kirin
Latest Information Update: 17 Jan 2007
Price :
$50
*
At a glance
- Originator Kirin Brewery; NanoCarrier
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Jan 2007 No development reported - Preclinical for Cancer in Japan (unspecified route)
- 07 Apr 2003 Preclinical trials in Cancer in Japan (unspecified route)